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Abstract
Background—Although the DASH (Dietary Approaches to Stop Hypertension) diet has been
shown to lower blood pressure (BP) in short-term feeding studies, it has not been shown to lower
BP among free-living individuals, nor has it been shown to alter cardiovascular biomarkers of risk.
Objective—To compare the DASH diet alone or combined with a weight management program
with usual diet controls among participants with prehypertension or stage 1 hypertension (systolic
BP, 130–159 mm Hg; or diastolic BP, 85–99 mm Hg).
Design and Setting—Randomized, controlled trial in a tertiary care medical center with
assessments at baseline and 4 months. Enrollment began October 29, 2003, and ended July 28,
2008.
Participants—Overweight or obese, unmedicated outpatients with high BP (N = 144).
Interventions—Usual diet controls, DASH diet alone, and DASH diet plus weight management.
Outcome Measures—The main outcome measure is BP measured in the clinic and by
ambulatory BP monitoring. Secondary outcomes included pulse wave velocity, flow-mediated
dilation of the brachial artery, baroreflex sensitivity, and left ventricular mass.
Results—Clinic-measured BP was reduced by 16.1/9.9 mm Hg (DASH plus weight
management); 11.2/7.5 mm (DASH alone); and 3.4/3.8 mm (usual diet controls) (P < .001). A
similar pattern was observed for ambulatory BP (P < .05). Greater improvement was noted for
DASH plus weight management compared with DASH alone for pulse wave velocity, baroreflex
sensitivity, and left ventricular mass (all P < .05).
Conclusion—For overweight or obese persons with above-normal BP, the addition of exercise
and weight loss to the DASH diet resulted in even larger BP reductions, greater improvements in
vascular and autonomic function, and reduced left ventricular mass. Key words: Hypertension,
Exercise, DASH diet, Blood pressure, Left ventricular mass
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The seventh report of the Joint National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure (JNC-7)1 recommends that lifestyle modifications
should be the initial treatment strategy for lowering blood pressure (BP). In addition to
advocating weight reduction, physical activity, dietary sodium reduction, and moderation of
alcohol consumption, as recommended by earlier guidelines,2 JNC-7 endorses the DASH
(Dietary Approaches to Stop Hypertension) diet for patients with elevated BP. Evidence
supporting the efficacy of this diet comes primarily from the DASH feeding trials, in which
a diet high in low-fat dairy products, fruits, and vegetables; lower in fats; and rich in fiber
significantly lowered clinic-measured BP with or without sodium reduction.3–5 The
PREMIER study6 subsequently demonstrated that the “established”(JNC-6) lifestyle
modifications and lifestyle modifications plus the DASH diet (JNC-7) were associated with
larger BP reductions compared with “advice only” controls; however, the BP differences
between the JNC-7 recommendations and the previously established (JNC-6) treatment
recommendations were small (<1 mm Hg) and not statistically significant. Therefore,
although the DASH diet has been shown to lower BP in short-term feeding studies, it has not
been shown to lower BP independent of other lifestyle changes among free-living
individuals. Because the clinical significance of high BP is derived from morbid events that
are not directly caused by elevated BP, but rather the associated structural and functional




The sample consisted of healthy, but overweight, men and women with above-normal BP.
Persons were eligible for study inclusion if they were not taking antihypertensive medication
and had a mean systolic BP (SBP) of 130 to 159 or diastolic BP (DBP) of 85 to 99 mm Hg
based on 4 screening visits. Other inclusion criteria included age 35 years or older, body
mass index of 25 to 40 (calculated as weight in kilograms divided by height in meters
squared), being sedentary, having no other medical comorbidities that would preclude safe
participation in the trial, and use of any medications known to affect the cardiovascular
system.
Trial Overview
The ENCORE (Exercise and Nutrition interventions for CardiOvasculaR hEalth) study was
approved by the Institutional Review Board at Duke University Medical Center. Written
informed consent was obtained from all participants.
Enrollment began October 29, 2003, and ended July 28, 2008. Participants were recruited
from physician referrals, community-based screenings, and mass media advertisements.
Eligibility was established during a series of screening visits that included a medical history
and physical examination, measurement of height and weight, and determination of baseline
clinic-measured BP. Following completion of baseline assessments, participants were
randomized to the DASH diet alone (DASH-A), the DASH diet combined with a behavioral
weight management program (DASH-WM), or to the usual diet control (UC) group. At the
end of the 4-month treatment period, assessments were repeated.
Assessments
Clinic-Measured BP—Clinic-measured BP was determined according to JNC-7
guidelines. Potential participants were asked to refrain from smoking or ingesting caffeine
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for at least 30 minutes before their appointment time. Measurements were standardized for
cuff size, position, environment, and time of day. After 5 minutes of quiet rest, 4 seated BP
readings, each 2 minutes apart, were obtained using a standard mercury sphygmomanometer
and stethoscope. We also obtained simultaneous automated BP recordings using an Accutorr
Plus BP monitor (Datascope, Mahwah, New Jersey)7 to provide an objective secondary
approach to clinic BP measurement. This clinic BP measurement protocol was repeated on 4
screening sessions over a 3 to 4 week period.
Ambulatory BP Monitoring—To assess BP during a typical day, participants wore an
Accutracker II (Suntech Medical Inc, Raleigh, North Carolina) ambulatory BP monitor.8
The Accutracker was programmed to record BP measurements 4 times per hour throughout
the waking hours and 2 times per hour during sleep. The mean BP during the entire 24-hour
monitoring period, adjusted for posture, was used for the primary analysis.
Pulse Wave Velocity—Pulse wave velocity (PWV), measured using the Complior device
(Artech Medical, Pantin, France), was used as an index of central artery stiffness.9 Pulse
pressure waveforms were recorded from the right carotid and right femoral arteries, and
PWV (meters per second) was calculated from measurements of pulse transit time (in
seconds) and the distance (in meters) traveled by the pulse between the 2 recording sites.
Flow-Mediated Dilation—Brachial artery flow-mediated dilation (FMD) was assessed
following overnight fasting.10 Longitudinal B-mode ultrasonographic images of the brachial
artery, 4- to 6-cm proximal to the antecubital crease, were obtained using an Aspen
ultrasound platform with an 11-MHz linear array transducer (Acuson, Mountain View,
California). Images were obtained after 10 minutes of supine relaxation and during reactive
hyperemia, induced by inflating a forearm occlusion cuff to suprasystolic pressure
(approximately 200 mm Hg) for 5 minutes. End-diastolic arterial diameters were measured
as the distance between the proximal and distal arterial wall intima-media interfaces using
PC-based software (Brachial Analyzer, version 4.0; Medical Imaging Applications LLC,
Iowa City, Iowa). Flow-mediated dilation was defined as the maximum percentage change
in arterial diameter relative to resting baseline from 10 to 120 seconds after deflation of the
occlusion cuff.
Baroreflex Sensitivity—Beat-by-beat SBP and heart rate (HR) were collected using the
Finapres noninvasive BP monitor (model 2300; Ohmeda, Madison, Wisconsin). Recordings
of beat-by-beat SBP and R-R interval (derived as 60 000/HR) were edited for artifacts,
linearly interpolated, and resampled at a frequency of 4 Hz to generate an equally spaced
time series. A fast Fourier transform was then applied to the interpolated data after
detrending and application of a Hanning filtering window. Baroreflex sensitivity (BRS) was
estimated from the magnitude of the transfer function relating R-R interval oscillations to
SBP oscillations across the 0.07 to 0.1299 Hz, or low-frequency, band. Coherence between
SBP and R-R interval oscillations was required to be at least 0.5 for measurements to be
accepted as estimates of BRS.
Left Ventricular Mass Index—Two-dimensional echocardiograms were acquired using
an Aspen imaging system and stored in a digital format for subsequent quantification by a
single observer (A.H.) who was blinded to treatment group. Left ventricular (LV) end-
diastolic diameter, posterior wall thickness, and interventricular septal thickness were
measured at end-diastole, using a leading edge–to–leading edge convention. Left ventricular
mass was estimated using a cube function model with a correction factor.11 To adjust for
variations in heart size owing to differences in body size, the LV mass index was calculated
as LV mass divided by height2.7 as described by de Simone et al.12
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Nutritional and Weight Assessment—An independent assessment of dietary and
nutritional content was obtained by 2 separate self-report measures of diet: a retrospective
food frequency questionnaire13 requiring participants to recall typical consumption during a
4-week period and a 4-day food diary. The food frequency questionnaire was analyzed by
NutritionQuest (Berkeley, California), and the diary data were analyzed using Food
Processor SQL Edition software, version 10.3 (ESHA Research, Salem, Oregon).14 In
addition, sodium, calcium, and potassium intake were estimated from urinary excretion
during a 24-hour period.15 Body weight was determined by a calibrated digital scale
(Detecto; Cardinal Scale Manufacturing Co, Webb City, Missouri).
Cardiorespiratory Fitness—Participants underwent a maximal graded exercise treadmill
test in which workloads were increased at a rate of 1 metabolic equivalent per minute.16
Expired air was collected by mouthpiece for quantification of minute ventilation, oxygen
consumption, and carbon dioxide production with the Parvo Medics TrueOne measurement
system (model 2400; Parvo Medics, Sandy, Utah).
Randomization—On completion of the baseline assessments, participants were
randomized in groups of 2 to 5 participants using a computer program. The size of the group
was determined by how many eligible participants were available to be randomized within 4
weeks of their baseline BP assessments. Participants were provided their treatment group
assignments in sealed envelopes; staff members performing the assessments were unaware
of the group assignments. Assignments were stratified by clinic-measured BP, body mass
index, and age.
Interventions—Immediately following randomization, participants entered a 2-week
controlled feeding period in which they ate according to the assigned dietary patterns
(control diet, DASH diet, or a reduced-calorie DASH diet). For the UC and DASH-A arms,
participants consumed study meals isocalorically so they would not gain or lose weight,
whereas participants in the DASH-WM arm consumed meals at a 500-calories-per-day
deficit to allow weight loss of about 1 pound a week. During the controlled feeding period,
body weight was measured every other day to monitor participants’ weight stability or loss,
allowing for adjustments in caloric intake. In addition, participants who were assigned to
DASH-A or DASH-WM met with the nutritionist twice weekly for instruction about the
DASH pattern. A 7-day menu cycle from the DASH-Sodium study for each dietary pattern
at each of the 1600, 2100, 2600, 3100, and 3600 kcal energy levels was used as the basis for
the recommended diets.17 We based caloric intake on the Harris Benedict formula, using
screening weights and estimated physical activity levels derived from the Seven-Day
Physical Activity Recall survey.18
The control diet contained 34% of calories from fat (the average level for Americans based
on the National Health and Nutrition Examination Survey Phase III19 data), whereas
potassium, magnesium, calcium, and fiber levels were set at approximately the 25th
percentile for average American intakes. Protein accounted for 15% of calories in the
control diet and 18% in the DASH diet. The DASH diet is reduced in total fat (27%),
saturated fat (6%), and cholesterol and contains about 3 times as much dietary fiber,
potassium, magnesium, and calcium as the control diet. Because severe sodium restriction
made a relatively small difference for those on the DASH diet,5 we used the current national
recommended level (2400 mg/d per 2000 kcal). Following the initial 2 weeks of controlled
feeding, participants were instructed to maintain the DASH diet on their own with (DASH-
WM) or without (DASH-A) weight loss.
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DASH Diet Alone—Participants in the DASH-A condition only received instruction in
modifying the content of their diet to meet DASH guidelines. Participants in this group were
explicitly asked not to exercise or to attempt to lose weight and to focus their attention only
on what they ate. Participants received counseling on the DASH diet and were provided
feedback on their adherence to the diet in weekly 30- to 45-minute small group sessions led
by the study nutritionist. The goal of the weekly sessions was to assist participants in
learning how to buy and prepare the appropriate foods, to enhance their motivation to
choose to eat those foods, and to overcome obstacles to following the diet. Participants also
were weighed each week to monitor their weight and to make adjustments in the
recommended servings so that their weight would remain stable during the intervention
period.
DASH Diet Plus Weight Management—Participants in the DASH-WM condition
received the same instruction in the DASH diet as the DASH-A group, but their weekly 30-
to 45-minute small group sessions also included a weekly cognitive-behavioral weight loss
intervention and they attended supervised exercise sessions 3 times per week.
Cognitive-Behavioral Weight Loss—This intervention was based on cognitive-
behavioral strategies20 and included Appetite Awareness Training,21 a self-monitoring
strategy in which individuals learn to identify internal cues of moderate hunger and fullness
and to use these cues to guide their eating behavior. The DASH recommendations were used
to provide guidance regarding what to eat, whereas cognitive-behavioral strategies were
designed to help individuals learn when/how to eat.
Supervised Exercise—Participants had supervised exercise sessions 3 times per week at
a level of 70% to 85% of their initial heart rate reserve determined at the time of the baseline
treadmill test. The supervised exercise routine consisted of 10 minutes of warm-up
exercises, 30 minutes of biking and/or walking or jogging, and 5 minutes of cool-down
exercises.
Usual Diet Controls—Participants in the UC condition were asked to maintain their usual
dietary and exercise habits for 4 months until they were reevaluated. On a biweekly basis,
their weight and BP were monitored and their health habits were assessed to ensure that they
had not joined any exercise or weight-loss program and had maintained their body weight.
Statistical Analysis
The effect of treatment on the primary and secondary outcomes was evaluated using the
general linear model function in SAS statistical software, version 9.1 (SAS Institute, Cary,
North Carolina). Separate models were estimated for each outcome. The predictors in each
model were 2 indicator variables carrying the orthogonal contrasts (DASH-WM and DASH-
A vs UC and DASH-WM vs DASH-A) and the corresponding pretreatment value of the
outcome, age, sex, and ethnicity (white vs nonwhite). We also adjusted for posture in the
analysis of ambulatory BP and for arterial diameter at rest in the FMD analysis. With respect
to changes in aerobic capacity, exercise endurance, and weight-related variables, where
DASH-WM was expected a priori to differ from the other 2 groups, we used 2 planned
contrasts: DASH-WM vs DASH-A and DASH-WM vs UC. Data for all outcomes were
analyzed following the intent-to-treat principle, with missing data managed using the
multiple imputation method available in SAS PROC MI. We estimated that we would have
about 80% power to detect a 0.5-SD difference between the active treatments and UC and a
0.6-SD difference between the 2 active treatments.
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Participant Flow—Of the 3129 participants who initially inquired about the study, 449
(32.1) met our initial inclusion criteria. After screening, 144 participants (32.2%) were
randomized: 49 to the DASH-WM condition (34.0%); 46 to DASH-A (31.9%); and 49 to
UC (34.0%) (Figure 1).
Participant Characteristics—The mean age of the sample was 52 years; 38.9% of
participants were African American, and 67.4% were women; the mean clinic-measured BP
was 138/86 mm Hg. Most participants were college-educated and relatively affluent. The
groups were generally comparable across the background variables (Table 1).
Attendance at Diet and Exercise Sessions—Attendance at the exercise and diet
classes was excellent. Of the 42 expected exercise sessions, the median number attended
was 38 sessions (90%). The median percentage time spent in the target HR range during
exercise was 94%. The DASH class attendance also was excellent; for both intervention
groups, the median number of sessions attended was 12 (92%).
Changes in Body Weight—Adjusting for initial weight, age, sex, and ethnicity, the
mean posttreatment weight for the DASH-WM group was significantly lower (84.5 kg)
compared with the DASH-A (92.9 kg; P <.001) and UC (94.1 kg; P <.001) groups. The
weight change was −8.7 kg in the DASH-WM group, −0.3 kg in the DASH-A group, and
0.9 kg in the UC group.
Changes in Dietary Intake and Urinary Excretion—Participants in the 2 DASH
treatment conditions showed excellent adherence to the DASH guidelines compared with
those randomized to UC (Table 2). Participants in the DASH-WM condition also consumed
significantly fewer total calories, less total protein, and fewer carbohydrates compared with
those in DASH-A.
Compared with UC, DASH-WM resulted in significantly lower urinary sodium levels and
higher urinary potassium excretion (P < .01) (Table 3). The DASH-WM and DASH-A
participants did not differ on any of the urinary excretion measures.
Changes in Aerobic Fitness—The DASH-WM group exhibited greater improvements
in peak V O2 (oxygen consumption) and exercise endurance compared with the DASH-A
and UC groups. Adjusting for pretreatment levels, age, sex, and ethnicity, the mean
posttreatment peak V O2 was higher among the DASH-WM participants (29 mL/kg/min)
compared with those randomized to the DASH-A (23 mL/kg/min; P <.001) or UC (22 mL/
kg/min; P <.001) condition. Participants in the DASH-WM group showed a 19% increase in
peak V O2 compared with negligible changes for participants in the DASH-A (−1.2%) and
UC (−3.2%) conditions.
Primary End Points
Blood Pressure—Compared with UC, the active treatments significantly lowered SBP (P
< .001) and DBP (P < .001) (Figure 2). In addition, compared with DASH-A, the DASH-
WM intervention resulted in significantly lower SBP (P = .02) and DBP (P < .048).
Expressed as adjusted change from pretreatment to posttreatment, the reduction in SBP was
16.1 (95% confidence interval, 13.0–19.2) mm Hg in the DASH-WM group, 11.2 (8.1–14.3)
mm Hg in the DASH-A group, and 3.4 (0.4–6.4) mm Hg in the UC group; the reduction in
DBP was 9.9 (8.1–11.6) mm Hg in the DASH-WM group, 7.5 (5.8–9.3) mm Hg in the
DASH-A group, and 3.8 (2.2–5.5) mm Hg in the UC group. The contrast between active
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treatments (DASH-A and DASH-WM) and UC also was significant for machine-read SBP
(P < .001) and DBP (P < .001); in addition, the machine-read BP values were lower for the
DASH-WM group compared with the DASH-A group for SBP (P = .01) and DBP (P = .06).
Moreover, at the end of treatment, 19 (38.8%) UC group participants were classified as
hypertensive (clinic BP >140/90 mm Hg) compared with only 6 (12.2%) in the DASH-WM
and 7 (15.2%) in the DASH-A groups.
Eighteen participants had missing or inadequate ambulatory BP readings either at baseline
or posttreatment. These missing assessments were imputed using a multiple imputation
model. Compared with the UC group, participants in the active treatment groups had
significantly lower ambulatory SBP and DBP (P < .001) (Figure 3). Ambulatory BPs were
lower in the DASH-WM group compared with the DASH-A group for SBP (P = .01) and
DBP (P = .03). Expressed as adjusted change from pretreatment to posttreatment, the
reductions in ambulatory BP were: DASH-WM group, 10.2 (95% confidence interval, 6.8 to
13.6)/5.4 (3.4 to 7.4) mm Hg; DASH-A group, 5.3 (2.0 to 8.6)/2.9 (1.0 to 4.9) mm Hg; and
UC group, 0.2 (3.4 to 7.4)/0.003 (−1.8 to 1.9) mm Hg.
Cardiovascular Biomarkers—The 2 DASH diet interventions resulted in lower PWV
compared with the UC group (P = .001), and PWV was lower in the DASH-WM group
compared with the DASH-A group (P = .045) (Figure 4). The 2 DASH treatment groups
also tended to exhibit larger improvements in FMD than the UC group (P = .06), but they
did not differ from one another (P = .99). For BRS, posttreatment results in the active
treatment groups were not different than those in the UC group (P = .38); however, greater
improvements were seen in DASH-WM compared with DASH-A (P = .01). The active
treatment groups had lower posttreatment values for LV mass index compared with the UC
group, but this difference was not significant (P = .26); however, the DASH-WM
intervention resulted in lower LV mass than did DASH-A (P = .02).
DISCUSSION
Results of this randomized controlled trial demonstrate that the DASH diet produces
significant reductions in BP compared with a typical American diet among unmedicated,
overweight or obese men and women with high BP and that weight loss and exercise
combined with the DASH diet produce additional BP lowering. Compared with UC, we
observed a 12.5/5.9 mm Hg net benefit in clinic-measured BP with the DASH-WM program
consisting of aerobic exercise, caloric restriction, and cognitive-behavioral intervention and
a 7.7/3.6 mm Hg net benefit with DASH-A. These findings confirm the value of the DASH
diet in reducing BP and provide evidence for the significant “added value” associated with
exercise and weight loss in the context of the DASH diet.
The efficacy of the DASH diet initially was established on the basis of several controlled
feeding trials designed to examine the effects of dietary patterns on BP among unmedicated
persons with higher-than-optimal DBP or with stage 1 hypertension; as a result of these
studies, the DASH diet was adopted as part of current national recommendations for the
prevention and treatment of high BP.1 The subsequent PREMIER study6 demonstrated the
feasibility of implementing the DASH diet in daily life, but the small and nonsignificant BP
differences between the DASH diet and the “established” intervention (which also involved
some dietary changes) raised doubts about the added value of the DASH diet in optimizing
BP. Because participants in the DASH plus “established” intervention lost more weight than
the “established” intervention alone, the effects of the DASH diet could not be determined.
The ENCORE trial has now extended the PREMIER study by not only examining the extent
to which lifestyle modifications can be adopted in the home environment but also by
manipulating the DASH diet intervention and weight loss independently. Our results
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confirm the findings of the earlier DASH feeding studies: participants who ate the DASH
diet achieved significant BP reductions.3–5 However, adding exercise and weight loss led to
an even greater decrease in BP.
The BP reductions achieved in our DASH-A and DASH-WM interventions were greater
than those described in the PREMIER study and in other trials of lifestyle modification.22–24
The reasons for the greater benefit from the current ENCORE intervention could be
attributed to the greater weight loss and excellent adherence to the DASH diet and exercise
sessions. The 12/6 mm Hg relative reduction in BP that we observed among participants
randomized to DASH-WM is equivalent to the BP lowering that physicians could expect
from a high dose of an antihypertensive drug.25 Similar BP reductions have been achieved
in placebo-controlled treatment trials and have resulted in a lowering of stroke risk by
approximately 40% and a reduction in ischemic heart disease events by about 25%.26
In addition to BP lowering, we demonstrated improvements in important cardiovascular
biomarkers. One of the structural consequences of high BP, left ventricular hypertrophy
(LVH), is the strongest known predictor, other than advancing age, of cardiovascular
morbidity and mortality. Increased LV mass predicts these clinical outcomes in
hypertensive27 and healthy individuals,28 independent of other conventional risk factors.
Drug therapy that results in LVH regression29 is associated with improved cardiovascular
outcomes. For example, Verdecchia et al30 found a lower risk of cardiovascular events in
hypertensive participants who had a decrease in LV mass during treatment, independent of
baseline BP or the degree of BP reduction. Similarly, in a substudy of the Losartan
Intervention of Endpoint Reduction in Hypertension (LIFE) trial, lowered LV mass was
associated with decreased rates of cardiovascular events.31
Arterial stiffness also has been shown to be a strong independent predictor of cardiovascular
morbidity and mortality.32–35 The DASH-A and the DASH-WM interventions resulted in
greater reductions in PWV than did UC, with more pronounced reductions among the
DASH-WM participants. Dietary sodium intake was reduced by approximately 30%
compared with UC, and participants in the DASH-WM group achieved a 19% improvement
in aerobic capacity, which may have augmented the benefits of the DASH diet and weight
loss on arterial stiffness. The observed reductions in PWV may be a result of the direct
impact of diet and exercise as well as the lower BP resulting from these lifestyle changes. A
reduction in arterial stiffness may also contribute to regression of LVH. The Ohasama study
showed that arterial stiffness measured by PWV was related to LVH, independent of age and
BP, in a population of 798 older adults.36 Ongoing trials should help clarify whether
reducing arterial stiffness contributes to a lowered risk for cardiovascular events.37
Impairment of the sensitivity of the baroreflex system is an early consequence of
hypertension38– 41 and likely reflects reduced viscoelastic properties of the vascular wall
housing the baroafferent stretch receptors owing to arterial stiffness and
atherosclerosis.42– 44 The DASH-A intervention did not alter BRS, but DASH-WM
improved BRS by 33%. The improvements in BRS may result from reduced vascular
stiffness45– 47 or improved parasympathetic cardiac control through improved insulin
sensitivity and glucose metabolism secondary to exercise and weight loss.48
The present study is limited by its relatively small sample of highly motivated participants
along with a labor-intensive treatment program that may be difficult to fully implement in
clinical practice. The ENCORE study was not powered to detect differences in “hard”
clinical end points, such as stroke, myocardial infarction, and death. Trials of pharmacologic
therapy, however, demonstrate that BP lowering reduces the risk of cardiovascular events
and that the magnitude of BP reduction and reversal of cardiovascular structural changes
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associated with hypertension are key determinants of the effectiveness of therapy.49
Ultimately, the effects of the DASH diet and weight management will need to be evaluated
prospectively in a larger sample of participants; longer-term follow-up of ENCORE study
participants is currently ongoing. The present findings suggest that the DASH diet,
particularly when augmented by exercise and weight loss, can offer considerable benefit to
patients with high BP, not only through reductions in BP but through favorable modification
of biomarkers of disease risk.
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Participant flow in the ENCORE (Exercise and Nutrition interventions for CardiOvasculaR
hEalth) clinical trial. BMI indicates body mass index (calculated as weight in kilograms
divided by height in meters squared); BP, blood pressure; DASH, Dietary Approaches to
Stop Hypertension; and ITT, intent-to-treat.
Blumenthal et al. Page 13














Comparison of posttreatment means and 95% confidence intervals for clinic-measured blood
pressure (BP) using an intent-to-treat model, adjusted for age, sex, ethnicity, and
pretreatment BP. The contrasts between all active treatment groups and the usual diet
control (UC) group were significant for both systolic (A) and diastolic (B) BP (P < .001), as
were the contrasts between DASH-WM (Dietary Approaches to Stop Hypertension plus
weight management) vs DASH-A (DASH alone) for systolic BP (P = .02) and diastolic BP
(P = .048). The right panels display the pairwise differences (mean difference and 95%
confidence interval) between the treatment groups calculated from the adjusted
posttreatment means.
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Comparison of posttreatment means and 95% confidence intervals for 24-hour ambulatory
blood pressure (BP) using an intent-to-treat model, adjusted for age, sex, ethnicity,
percentage of time in sitting or standing position, and pretreatment BP. The contrast between
all active treatment groups and the usual diet control (UC) group was significant for systolic
(A) and diastolic (B) BP (P < .001), as were the contrasts between DASH-WM (Dietary
Approaches to Stop Hypertension plus weight management) vs DASH-A (DASH alone) for
systolic BP (P = .01) and diastolic BP (P = .03). The right panels display the pairwise
differences (mean difference and 95% confidence intervals) between the treatment groups
calculated from the adjusted posttreatment means.
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Comparison of posttreatment mean (95% confidence interval) values for pulse wave velocity
(A), flow-mediated dilation (B), baroreflex sensitivity (C), and left ventricular (LV) mass
index (D) by treatment group, adjusted for age, sex, ethnicity, and pretreatment level of
response variable. Flow-mediated dilation of the brachial artery also was adjusted for
pretreatment arterial diameter at rest. Results of contrasts were as follows: for pulse wave
velocity (A), all treatments vs usual diet controls (UC), P = .002, and DASH-WM (Dietary
Approaches to Stop Hypertension plus weight management) vs DASH-A (DASH alone), P
= .045; for flow-mediated dilation (B), all treatments vs UC, P = .06, and DASH-WM vs
DASH-A, P = .99; for baroreflex sensitivity (C), all treatments vs UC, P = .38, and DASH-
WM vs DASH-A, P = .01; and for left ventricular mass index (D), all treatments vs UC, P
= .26, and DASH-WM vs DASH-A, P = .02.
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